Mr. Luc Gregoire reports

DEVONIAN BOLSTERS INTELLECTUAL PROPERTY WITH ISSUANCE OF U.S. PATENT COVERING A METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE

The United States Patent and Trademark Office (USPTO) has issued patent No. 11,723,938 B2 to Devonian Health Group Inc., entitled "Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease," covering a method for treating inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease in a human subject with an effective amount of active thylakoid extract.

"We are pleased to add to our existing patent portfolio relating to thylakoids developed by the Company such as PUR0110, Thykamine(TM) ("Thykamine"). Thykamine continues to demonstrate its potential as a therapeutic platform targeting several inflammatory diseases. We believe Thykamine is differentiated from other drugs that are used to treat inflammatory diseases and this patent provides additional rationale for how it can provide unique benefits to potential patients. We plan to continue this work to further expand Thykamine's patent estate in our clinical development program focused on dermatological applications", said Andre P. Boulet PhD, Chief Scientific Officer of the Company.

About Thykamine

Thykamin, the first pharmaceutical product issued from the Company's SUPREX(TM) platform ("SUPREX"), is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a Phase II clinical study in patients with mild-to-moderate atopic dermatitis. Both Thykamine and SUPREX platform are protected by several patents in North America, Europe and Asia.

About Devonian

Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by the American Food and Drug Administration set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSX Venture Exchange (the "Exchange") (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

We seek Safe Harbor.